 |
217 Diseases |  |
226 Trials |
|
226 Trials |  |
3828 News |  |
| «12...89101112131415161718...4950» |
- | Pinorubin (pirarubicin) / Sanofi
Journal: Assessment of Therapeutic Benefit and Option Strategy on Intravesical Instillation for Preventing Bladder Cancer Recurrence after Radical Nephroureterectomy in Patients with Upper Urinary Tract Urothelial Carcinoma. (Pubmed Central) - Jun 10, 2022
In this retrospective cohort study, from October 2006 to September 2017, 158 UUT-UC patients underwent RNU were divided into 4 groups: epirubicin (EPB) instillation group, hydroxycamptothecin (HCPT) instillation group, bacillus Calmette-Guerin (BCG) instillation group, and noninstillation group...Then, a network meta-analysis including 7 studies indicated that pirarubicin (THP) (surface under the cumulative ranking curve [SUCRA] = 89.2%) is the most effective therapy to reduce the risk of bladder recurrence, followed by BCG (SUCRA = 83.5%), mitomycin C (MMC) (SUCRA = 53.6%), EPB (SUCRA = 52.6%), and HCPT (SUCRA = 5.1%) after the analysis of the value ranking...Compared with other chemotherapy regimens, THP may be a promising drug with favorable efficacy to prevent bladder recurrence. As included studies had moderate risk of bias, the results of network meta-analysis should be applied with caution.
- | Tyvyt (sintilimab) / Innovent Biologics
Enrollment closed, Trial completion date, Trial primary completion date: Anti-PD-1 Antibody Plus DEB-TACE for BCLC Stage A/B HCC (clinicaltrials.gov) - Jun 9, 2022
P2, N=61, Active, not recruiting, Sponsor: Zhejiang University
As included studies had moderate risk of bias, the results of network meta-analysis should be applied with caution. Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Nov 2020 --> Jul 2022
- | Epidaza (chidamide) / Chipscreen
Enrollment open, Combination therapy: Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC (clinicaltrials.gov) - Jun 5, 2022
P2, N=59, Recruiting, Sponsor: Shengjing Hospital
Recruiting --> Active, not recruiting | Trial completion date: May 2022 --> Dec 2022 | Trial primary completion date: Nov 2020 --> Jul 2022 Not yet recruiting --> Recruiting
- | lobaplatin (D19466) / AEterna Zentaris
Retrospective data, Journal: Efficacy and safety of lobaplatin-TACE in the treatment of primary hepatocellular carcinoma: A retrospective study. (Pubmed Central) - Jun 4, 2022
There was no statistical difference in the incidence rate of abdominal pain, fever and infection after TACE between the two groups (P=0.502,P=0.602,P=0.726).The incidence of vomiting after TACE in the lobaplatin-TACE group was higher than that in the epirubicin-TACE group (P=0.003). Conclusion Lobaplatin-TACE has higher tumor response rate and survival rate.Lobaplatin-TACE is a safe and effective treatment strategy,it is worthy of clinical application.
- | Epidaza (chidamide) / Chipscreen
New P2 trial, Combination therapy: Clinical Study of Chidamide Combined With Chemotherapy in Neoadjuvant Treatment of HR+/ HER2-BC (clinicaltrials.gov) - Jun 2, 2022
P2, N=59, Not yet recruiting, Sponsor: Shengjing Hospital
- | epirubicin / Generic mfg.
Journal: Muscle sparing latissimus dorsi flap for reconstruction of a large chemo-necrosis of the chest wall: A case report. (Pubmed Central) - May 31, 2022
Chemotherapeutics' extravasations can be a severe complication of oncologic treatment and have to be discussed between oncologists and plastic surgeons to find the most effective and suitable solution with consideration of the specificities of cancer therapy. In chest wall skin defect, the use of muscle sparing latissimus dorsi pedicled flap is a robust solution with low morbidity of the donor site.
- Systematic literature review of real-world outcomes of chemotherapies for advanced or recurrent endometrial cancer (Exhibition area) - May 30, 2022 - Abstract #ESMOGC2022ESMO_GC_95;
AEs (from 3 studies) were nausea (18.9%), palmar-plantar erythrodysesthesias (16.4%), and muscle weakness (12.3%) for doxorubicin, neurotoxicity (0%-10.6%) and hypersensitivity reaction (0%-2.4%) for PC, and neutropenia (16%) for carboplatin plus epirubicin. Conclusions The limited evidence found low OS and PFS for aEC following CT in both 1L and ≥2L settings, further emphasizing the high unmet need for new treatment options in this aggressive indication.
- || P2 data, Journal: The ACE trial: A randomized phase II study for advanced endometrial carcinoma. (Pubmed Central) - May 29, 2022
When compared to the current standard treatments for endometrial cancer, TEC is a promising candidate for a phase III trial based on its significantly superior CRate and equivalent PFS and OS. This study is registered with UMIN Clinical Trials Registry (UMIN000008911).
- | cisplatin / Generic mfg., epirubicin / Generic mfg.
Biomarker, Journal, BRCA Biomarker: A Crucial Angiogenesis-Associated Gene MEOX2 Could Be a Promising Biomarker Candidate for Breast Cancer. (Pubmed Central) - May 29, 2022
Finally, the Kaplan-Meier plotter confirmed that higher expression levels of MEOX2 were related to better overall survival. Our study revealed that the angiogenesis-associated gene MEOX2 can be used as a novel biomarker for breast cancer diagnosis and clinical therapy.
- ||| Herceptin (trastuzumab) / Roche, Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Clinical, P3 data, Journal: Efficacy of HD201 vs Referent Trastuzumab in Patients With ERBB2-Positive Breast Cancer Treated in the Neoadjuvant Setting: A Multicenter Phase 3 Randomized Clinical Trial. (Pubmed Central) - May 25, 2022
P3
The results of this randomized clinical trial found that HD201 demonstrated equivalence to referent trastuzumab in terms of efficacy for the end point of tpCR, with a similar safety profile. ClinicalTrials.gov Identifier: NCT03013504.
- MINIMAL ADDED VALUE OF WETTING HAIR BEFORE SCALP COOLING TO PREVENT CHEMOTHERAPY INDUCED ALOPECIA - RESULTS FROM THE DUTCH SCALP COOLING REGISTRY (Exhibition hall E-Poster Stage 3, Metropolitan Centre, CC) - May 22, 2022 - Abstract #MASCCISOO2022MASCC_ISOO_463;
Given the significant higher discontinuation due to intolerance in patients wetting their hair, it is not recommended to wet hair from patients on these chemotherapies. Results stress the need for studying chemotherapy types separately, as the one-size fits all approach seems to be unreliable.
- | paclitaxel / Generic mfg.
Journal: EVALUATION OF THE EFFICIENCY OF ALPHA-LIPOIC ACID AND IPIDACRINE HYDROCHLORIDE FOR THE PREVENTION OF PACLITAXEL-INDUCED PERIPHERAL NEUROPATHY ACCORDING TO THE TOTAL NEUROPATHY SCORE. (Pubmed Central) - May 22, 2022
Results stress the need for studying chemotherapy types separately, as the one-size fits all approach seems to be unreliable. Proposed combination of alpha-lipoic acid and ipidacrine hydrochloride led to a statistically significant reduction in the severity of PIPN, and thus to improvement of the functional capacity and quality of life of patients.
- ||| celecoxib oral / Generic mfg.
P3 data, Journal: Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). (Pubmed Central) - May 20, 2022
P3
A statistically significant interaction between treatment and hormone receptor status favoring AC in hormone-receptor-positive breast cancers is consistent with the hypothesis that optimal duration of chemotherapy may be four cycles in these patients. Late cardiac events and deaths prior to recurrence or second cancer were infrequent on both arms, but slightly higher with FEC-100.
- | Zadaxin (thymalfasin) / SciClone
Journal: Thymosin α-1 reverses M2 polarization of tumor-associated macrophages during efferocytosis. (Pubmed Central) - May 18, 2022
Tα-1 combined with epirubicin chemotherapy markedly suppressed tumor growth in an in vivo breast cancer model by reducing macrophage-derived IL-10 and enhancing the number and function of tumor-infiltrating CD4+ and CD8+ T cells. In conclusion, Tα-1 improved the curative effect of chemotherapy by reversing M2 polarization of efferocytosis-activated macrophages, suggesting that Tα-1 injection immediately after chemotherapy may contribute to highly synergistic anti-tumor effects in breast cancer patients.
- | Neulasta (pegfilgrastim) / Roche
Trial completion date: GIM2: Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer (clinicaltrials.gov) - May 18, 2022
P3, N=2000, Active, not recruiting, Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
In conclusion, Tα-1 improved the curative effect of chemotherapy by reversing M2 polarization of efferocytosis-activated macrophages, suggesting that Tα-1 injection immediately after chemotherapy may contribute to highly synergistic anti-tumor effects in breast cancer patients. Trial completion date: Dec 2022 --> Dec 2025
- epirubicin / Generic mfg.
INHIBITION OF MIF ENHANCES THE SENSITIVITY OF BREAST CANCER CELL TO EPIRUBICIN BY ACTIVATING NOX4/ROS PATHWAY () - May 16, 2022 - Abstract #GBCC2022GBCC_284;
Trial completion date: Dec 2022 --> Dec 2025 In summary, our findings suggested that MIF silencing enhanced the sensitivity of BC cells to epirubicin by Nox4/ROS axis, which might provide a new strategy for overcoming drug-resistance of BC.
- | capecitabine / Generic mfg.
Journal, BRCA Biomarker: Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients. (Pubmed Central) - May 15, 2022
Patients with BRCA1-like TNBC may also benefit. Additional research is needed to define the subgroup within BRCA1-like TNBC patients who may not benefit from adjuvant capecitabine.
- | epirubicin / Generic mfg.
Journal: Epirubicin-loaded beads transarterial prostatic arterial chemoembolization is a promising treatment for advanced prostate cancer with lower urinary tract obstruction or hematuria-a case series report. (Pubmed Central) - May 14, 2022
DEB-PACE is a promising treatment for advanced PC with lower urinary tract obstruction or hematuria. However, the efficacy and safety of DEB-PACE for advanced PC is needed to validated by prospective large sample randomized controlled study.
- | epirubicin / Generic mfg.
Journal: Facile fabrication of hypercrosslinked microporous polymer nanospheres for effective inhibition of triple negative breast cancer cells proliferation. (Pubmed Central) - May 12, 2022
In short, the inherent features of hypercrosslinked microporous polymers nanospheres (HMPNs) enabled the high encapsulation of Epirubicin (EPI) and its controlled release in TNBC cell lines (SUM-159 and MDA-MB-231) to inhibit cancer cells proliferation. We anticipate that the further development in functionalization of hypercrosslinked polymers may lead to a breakthrough in biomedical applications.
- | oxaliplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
Journal: Role of Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach: An Analysis of the Short-Term Outcomes. (Pubmed Central) - May 12, 2022
In view of high progression rates, patient selection is required when NACT is planned in carcinoma stomach which are surgically resectable at presentation. We await survival analysis to further validate the role of NACT.
- || Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka
Clinical, Journal: Feasibility Study of Nanoparticle Albumin-Bound-Paclitaxel and S-1 Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With Operable Breast Cancer: A Prospective Study. (Pubmed Central) - May 6, 2022
We await survival analysis to further validate the role of NACT. Tri-weekly nab-paclitaxel with S-1 followed by EC is effective and well tolerated as neoadjuvant chemotherapy in patients with operable breast cancer.
- | Herceptin (trastuzumab) / Roche
Journal: Response-Guided Omission of Anthracycline in Patients with HER2-Positive Early Breast Cancer Treated with Neoadjuvant Taxane and Trastuzumab: 5-Year Follow-up of Prognostic Study Using Propensity Score Matching. (Pubmed Central) - May 6, 2022
Using PSM, the 5-year DFS of HER2-positive early breast cancer was not different with or without anthracycline. Response-guided omission of anthracycline may be an option for HER2-positive early breast cancer patients receiving neoadjuvant taxane and trastuzumab with good response in order to avoid overtreatment.
- | Preclinical, Journal: Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening. (Pubmed Central) - May 6, 2022
Gemcitabine and L-OHP + EPI + irinotecan + 5-FU, L-OHP + EPI, and L-OHP + irinotecan + EPI were more effective against AFP-positive compared with AFP-negative liver cancer cells according to in vitro high-throughput drug sensitivity screening. These results may guide the selection of personalized drug treatments for patients with advanced liver cancer in the future but still need further clinical studies to confirm.
- | Apolactoferrin (talactoferrin alfa) / Agennix
Preclinical, Journal: Recombinant Human Lactoferrin Augments Epirubicin Chemotherapy in Solid Ehrlich Carcinoma Bearing Mice. (Pubmed Central) - May 6, 2022
Recombinant human lactoferrin exhibited potential anticancer and immuno-enhancing properties in mice with breast cancer. Co-treatment with rhLF and EPI proved to be a promising strategy in cancer treatment.
- | Trial completion date, Trial primary completion date: COC-IDCB: A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast (clinicaltrials.gov) - May 5, 2022
P1, N=300, Recruiting, Sponsor: Shanghai Jiao Tong University School of Medicine
Co-treatment with rhLF and EPI proved to be a promising strategy in cancer treatment. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- | Journal: Anemia requiring transfusion in breast cancer patients on dose-dense chemotherapy: Prevalence, risk factors, cost and effect on disease outcome. (Pubmed Central) - Apr 30, 2022
Anemia is a common toxicity associated with dose-dense chemotherapy during curative breast cancer treatment leading to delay in treatment and increased cost. Low-grade tumor, grade 3 or 4 thrombocytopenia, and grade 2 or higher anemia after two cycles of chemotherapy are risk factors for blood transfusions during treatment.
- | Herceptin (trastuzumab) / Roche
Journal: Baseline Mutations and Up-Regulation of PI3K-AKT Pathway Serve as Potential Indicators of Lack of Response to Neoadjuvant Chemotherapy in Stage II/III Breast Cancer. (Pubmed Central) - Apr 29, 2022
Compared to BC patients achieving pCR to NAC, aberrant activation of PI3K-AKT pathway genes were more frequently observed in patients not achieving pCR, consistent with the significant up-regulation of PI3K-AKT pathway gene expression in the non-pCR subgroup. Together, these findings indicate that upregulated PI3K-AKT pathway serves as a potential indicator of lack of response to NAC in stage II/III BC patients, and other effective therapeutic options are urgently needed for those resistant patients.
- Herceptin (trastuzumab) / Roche
Outcomes of neoadjuvant combination chemotherapy with and without targeted therapy in HER2-positive breast cancer: A real-world experience from tertiary care center in North India. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6414;
Trastuzumab containing regimens impact pCR rates and in turn the survival outcomes among Indian women with HER2 positive breast cancer. Safety and efficacy of anthracycline free TCH regimen is comparable with EC-TH.
- Herceptin (trastuzumab) / Roche
Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_6406;
P2/3
Pyrotinib, a new irreversible tyrosine kinase inhibitor (TKI), combined with capecitabine have demonstrated a promising anti-tumour activity in metastatic breast cancer...Cases were randomly assigned into neoadjuvant therapy with four cycles of epirubicin and cyclophosphamide followed by four cycles of docetaxel (or Paclitaxel for Injection, albumin bound) and trastuzumab (EC-TH), or pyrotinib (400mg day 1-21) combined with EC-TH... Pyrotinib added to EC-TH neoadjuvant therapy significantly increased the pCR rate, suggesting an applicable strategy for HER2-positive breast cancer.
- Homologous recombination deficiency predicts response to platinum-based neoadjuvant chemotherapy in early-stage triple-negative breast cancer patients: Secondary analysis of the neocart randomized clinical trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5951;
P2
Background: We recently performed the NeoCART trial to compare six cycles of docetaxel plus carboplatin (DCb) with four cycles of epirubicin/cyclophosphamide followed by four cycles of docetaxel (EC-D) in the neoadjuvant setting of triple-negative breast cancer (TNBC). PCR in TNBC patients correlated with a higher HRD score, higher stromal TILs, and a higher Ki67 index on carboplatin-based neoadjuvant chemotherapy regardless of BRCA status.
- AiTan (rivoceranib) / HLB Bio Group
Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): A single-center, single-arm, phase II trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5948;
P2
PCR in TNBC patients correlated with a higher HRD score, higher stromal TILs, and a higher Ki67 index on carboplatin-based neoadjuvant chemotherapy regardless of BRCA status. The combination of apatinib with docetaxel followed by the epirubicin plus cyclophosphamide showed excellent efficacy and manageable toxicities; further randomized controlled phase III trials are warranted.
- doxorubicin hydrochloride / Generic mfg., epirubicin / Generic mfg.
Short-term anthracyclines-induced cardiotoxicity in breast cancer patients. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4831;
Anthracycline-based chemotherapy has detrimental subclinical effect on electrical activity and left ventricle systolic function in the short term after adjuvant chemotherapy. We did not observe any significant effect of risk factors, it is therefore important to monitor all patients.
- Kadcyla (ado-trastuzumab emtansine) / Roche, Perjeta (pertuzumab) / Roche
Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3373;
>a Adjusted for intervention arm, tumor subtype, and tumor size. b Linear trends across tertiles of TK1 were tested by modeling the median value in each quintile as a continuous variable in Logistic regression.
- Neulasta (pegfilgrastim) / Amgen, Kyowa Kirin, Roche
Neoadjuvant therapy with concurrent anthracyclines and taxanes in Her2-negative breast cancer (HNBC): TAC legacy. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3371;
It has similar pCR and survivall to those reported in meta-analysis. GCSF facilitates treatment compliance but the risk of neutropenia and admissions are still present.
- Jinyouli (pegfilgrastim biosimilar) / CSPC Pharma
A randomized trial of pegylated recombinant human granulocyte-colony stimulating factor to prevent febrile neutropenia in breast cancer after chemotherapy. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_3370;
Preliminary results suggest a similar effect of PEG-rhG-CSF administration at 48 or 24 hours after chemotherapy in primary prevention of FN in breast cancer patients receiving EC chemotherapy regimen. Recruitment is ongoing and updated data will be presented.
- Keytruda (pembrolizumab) / Merck (MSD)
Event-free survival by residual cancer burden after neoadjuvant pembrolizumab + chemotherapy versus placebo + chemotherapy for early TNBC: Exploratory analysis from KEYNOTE-522. (Available On Demand) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3339;
P3
Pts with residual disease had lower RCB values in the pembro arm, including fewer pts with RCB-3. Pembro + chemo prolonged EFS vs chemo alone in the RCB-0, -1, and -2 categories; the small sample size limits interpretation in the RCB-3 category.
- Herceptin Hylecta (trastuzumab/hyaluronidase-oysk) / Roche, Halozyme
Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA). (Available On Demand; 385b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3319;
P2
Those with incomplete clinical response by breast ultrasound volume measurements receive 3 additional cycles of chemotherapy; cyclophosphamide 600mg/m2, epirubicin 90mg/m2 and 5-fluorouracil 600mg/m2 every 3 weeks before re-evaluation for surgery...Secondary objectives are to evaluate invasive disease-free survival (iDFS), the pattern of response and mechanisms of resistance to treatment based on genomic markers, the pharmacokinetics of Herceptin SC, quality of life, and adverse event rates, including cardiac toxicity...Progress: Accrual commenced on 3rd April 2020 and is 75% completed. To date, monitoring, regulatory, as well as Data Safety and Monitoring Board progress evaluation did not identify any logistical or safety issues such as underdeveloped infrastructure, unacceptable rate of non-compliance with study protocol, poor informed consent procedure or serious adverse events to warrant stopping the trial.
- Irene (pyrotinib) / Jiangsu Hengrui Medicine
Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial. (Available On Demand; 384b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3317;
P2
Primary efficacy outcomes will be analyzed in the intention‐to‐treat population and safety outcomes in the safety set population. Long-term efficacy outcomes will be assessed later with enough follow-up.
- Baize'an (tislelizumab) / BeiGene, Novartis, Focus V (anlotinib) / Advenchen, Sino Biopharm
Anlotinib plus tislelizumab combined with chemotherapy as neoadjuvant treatment in triple-negative breast cancer: A prospective, single-arm, open-label phase II study. (Available On Demand; 383b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3315;
P2
A sample size of 32 patients was estimated to provide a 80% power to detect a difference of 25% in pCR at a significance level of α = 0.05. The study was initiated in August 2021.
- cyclophosphamide / Generic mfg., docetaxel / Generic mfg.
The real-world experience of adjuvant docetaxel and cyclophosphamide (TC) chemotherapy in HER-2 negative breast cancer. (Available On Demand; 310) - Apr 28, 2022 - Abstract #ASCO2022ASCO_3236;
Patients treated with adjuvant TC who had four or more axillary LN had significantly lower OS when compared to patients with LN 0. For women with ER- disease, TC demonstrated a significant unfavourable survival outcome when compared to anthracycline-based treatments.
- epirubicin / Generic mfg., idarubicin hydrochloride / Generic mfg.
TACE with idarubicin-eluting beads compared with TACE with epirubicin-eluting beads in BCLC B-stage HCC: Interim results of a randomized, double-blind, parallel-controlled, phrase IV multicenter study. (Available On Demand; 56) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1907;
This study proved that Idarubicin could be a good safety profile and superior PFS and ORR than Epirubicin when used as part of a TACE regimen for BCLC B stage HCC. Longer follow-up is needed to confirm this conclusion.
- dexamethasone / Generic mfg.
Efficacy and safety of dexamethasone-based mouthwash to prevent chemotherapy-induced stomatitis in women with breast cancer: A multicenter, open-label, randomized phase II study. (Available On Demand; 348) - Apr 28, 2022 - Abstract #ASCO2022ASCO_910;
Patients with early-stage breast cancer scheduled for epirubicin and cyclophosphamide (EC) or docetaxel and cyclophosphamide (TC) therapies were allocated in a 1:1 ratio to the intervention and control groups. Dexamethasone-based mouthwash safely reduced the incidence and severity of stomatitis in patients receiving chemotherapy (EC/TC) for early breast cancer.
- || epirubicin / Generic mfg.
PK/PD data, Journal: Determination of the effect of berberine on epirubicin concentration in MCF-7 cells by LC-MS/MS: The mechanism of synergism explained by intracellular pharmacokinetics. (Pubmed Central) - Apr 27, 2022
The results suggest that berberine may enhance the inhibitory effect of epirubicin on cell proliferation by increasing the concentration of epirubicin in MCF-7 cells. The assay provides a basis for research on the intracellular pharmacokinetics of epirubicin and develops analytical methods for other cell-targeted drugs.
- | docetaxel / Generic mfg., epirubicin / Generic mfg.
Trial completion, Trial completion date, Tumor cell: Secondary Adjuvant Treatment for Patients With Isolated Tumor Cells in Bone Marrow (clinicaltrials.gov) - Apr 22, 2022
P2, N=1128, Completed, Sponsor: Oslo University Hospital
The assay provides a basis for research on the intracellular pharmacokinetics of epirubicin and develops analytical methods for other cell-targeted drugs. Active, not recruiting --> Completed | Trial completion date: Dec 2022 --> Apr 2022
- || dactinomycin / Generic mfg., vincristine / Generic mfg.
Clinical, Journal: Outcome of SIOP patients with low- or intermediate-risk Wilms tumour relapsing after initial vincristine and actinomycin-D therapy only - the SIOP 93-01 and 2001 protocols. (Pubmed Central) - Apr 22, 2022
Patients with relapsed WT after initial VA-only treatment showed no inferior EFS and OS when treated with VAD regimens compared with more intensive rescue regimens. A subset of patients relapsing after VA may benefit from less intensive rescue treatment than ICE/CyCED-based regimens and deserve to be pinpointed by identifying additional (molecular) prognostic factors in future studies.
- | Journal: Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma - A comparison of the FLOT and 'MAGIC' regimens. (Pubmed Central) - Apr 22, 2022
Patients with oesophageal or gastric adenocarcinoma treated with peri-operative FLOT had better survival and pathological response than those treated with peri-operative MAGIC. Rates of surgical complications, adverse events and chemotherapy completion were comparable.
- ||| oxaliplatin / Generic mfg., capecitabine / Generic mfg., epirubicin / Generic mfg.
P3 data, Journal: XELOX doublet regimen versus EOX triplet regimen as first-line treatment for advanced gastric cancer: An open-labeled, multicenter, randomized, prospective phase III trial (EXELOX). (Pubmed Central) - Apr 22, 2022
This non-inferiority trial demonstrated that the doublet regimen was as effective as the triplet regimen and had a better safety profile and QoL as a first-line treatment for AGC patients. However, the triplet regimen might have a survival advantage in patients with poorly differentiated adenocarcinoma and liver metastasis.
- | irinotecan / Generic mfg., epirubicin / Generic mfg.
Retrospective data, Journal: Percutaneous Thermal Segmentectomy: Proof of Concept. (Pubmed Central) - Apr 22, 2022
b-MWA followed by b-TACE in a single-step procedure led to larger necrotic areas than the proposed by vendors ablation chart, non-spherical in shape and corresponded to the vascular segment occluded during ablation. This permitted to safely achieve promising oncological results in patients with > 3 cm tumors.
- ||||||| Hervelous (trastuzumab biosimilar) / Hanwha Solutions, Alvogen, Prestige BioPharma, Mundipharma, Dr. Reddy's
Trial completion: TROIKA: A Phase III Trial to Compare the Efficacy, Safety and Pharmacokinetics of HD201 to Herceptin (clinicaltrials.gov) - Apr 22, 2022
P3, N=503, Completed, Sponsor: Prestige Biopharma Limited
This permitted to safely achieve promising oncological results in patients with > 3 cm tumors. Active, not recruiting --> Completed
- ||| albumin-bound paclitaxel / Generic mfg.
New trial: Effectiveness of Cryotherapy Combined With Compression Therapy for Preventing Chemotherapy-induced Peripheral Neuropathy (clinicaltrials.gov) - Apr 21, 2022
P=N/A, N=102, Not yet recruiting, Sponsor: Peking University